Effects of Advair® in Outpatients With Chronic Obstructive Pulmonary Disease (COPD) Acute Exacerbation

PHASE3CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
DRUG

prednisone group

Patients in the prednisone group will receive prednisone 40 mg per day with concomitant placebo diskus 2 inhalations twice a day for 10 days. All patients will receive oral antibiotics for 10 days, which will include moxifloxacin (Avelox®) 400 mg die or amoxicillin/clavulanate (Clavulin®) 875mg bid and short-acting bronchodilators (Ventolin®, Bricanyl®, Atrovent®) as needed.

DRUG

Advair group

Patients in the second group will receive Advair® 50/500 ug 2 inhalations twice daily with placebo pills once a day for 10 days (twice the regular dosage). All patients will receive oral antibiotics for 10 days, which will include moxifloxacin (Avelox®) 400 mg die or amoxicillin/clavulanate (Clavulin®) 875mg bid and short-acting bronchodilators (Ventolin®, Bricanyl®, Atrovent®) as needed.

Trial Locations (1)

G1V 4G5

Hôpital Laval, Institut universitaire de cardiologie et de pneumologie, Québec

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Laval University

OTHER